摘要
背景与目的:人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)阳性乳腺癌患者的肿瘤免疫微环境(tumor immune microenvironment,TIME)与曲妥珠单抗治疗效果显著相关,提示免疫检查点疗法联合曲妥珠单抗治疗的临床潜力。本研究旨在探索HER2阳性乳腺癌联合治疗的预测因子,筛选联合治疗的潜在获益人群。方法:纳入高通量基因表达(Gene Expression Omnibus,GEO)数据库中509例接受曲妥珠单抗治疗的HER2阳性乳腺癌患者和癌症基因组图谱(The Cancer Genome Atlas,TCGA)数据库中67例HER2阳性乳腺癌患者的转录组与基因组数据,筛选曲妥珠单抗耐药组的差异表达基因进行功能富集分析、蛋白质互作网络构建。结合临床信息通过对数秩检验和多因素COX比例风险回归模型构建预测模型。并利用CIBERSORT反卷积法分析TIME特征,通过肿瘤免疫功能障碍和排斥(tumor immune dysfunction and exclusion,TIDE)评分预测免疫治疗获益。结果:通过分析曲妥珠单抗缓解组和曲妥珠单抗耐药组之间的免疫微环境与基因表达特征,构建了由4个核心基因(GATA6、TRPV6、AMACR、ZHX2)组成的曲妥珠单抗相关基因预测指数(trastuzumab related genetic prognostic index,TRGPI)。低TRGPI评分的患者的TIME含有更高比例的CD8+T淋巴细胞和激活的自然杀伤细胞,同时程序性死亡[蛋白]-1(programmed death-1,PD-1)的表达更高,更倾向于从曲妥珠单抗联合免疫治疗中获益。结论:本研究基于TIME重新定义了HER2阳性乳腺癌曲妥珠单抗联合免疫治疗的获益人群,并为临床应用提供了可选的治疗策略。
Background and Purpose:The tumor immune microenvironment(TIME)of breast cancer with positive human epidermal growth factor receptor 2(HER2)is significantly related to the efficacy of trastuzumab,indicating the clinical potential of immunocheckpoint therapy combined with trastuzumab.This study aimed to explore the predictors of HER2-positive breast cancer combination therapy and screen the potential beneficiaries of combination therapy.Methods:Transcriptome and genome data of 509 HER2-positive breast cancer samples of patients receiving trastuzumab treatment from Gene Expression Omnibus(GEO)database and 67 HER2-positive breast cancer samples from The Cancer Genome Atlas(TCGA)databases were collected.Trastuzumabresistant group’s differentially expressed genes were identified and analyzed for functional enrichment and protein-protein interaction.The log-rank test and multivariate COX proportional hazards regression were used with clinical data to create the prediction model.The TIME landscape was characterized using the CIBERSORT.The immunotherapy benefit was valued by the tumor immune dysfunction and exclusion(TIDE)score.Results:The trastuzumab related genetic prognostic index(TRGPI)consisting of four hub genes(GATA6,TRPV6,AMACR,ZHX2)was constructed by analyzing the immune microenvironment and gene expression characteristics between trastuzumab-remission group and trastuzumab-resistance group.Importantly,the results revealed that patients with lower TRPGI were trastuzumab-sensitive and more likely to benefit from immunotherapy because of the increased percentages of CD8+T cells,active natural killer cells and programmed death-1(PD-1)expression.Conclusion:This study redefined the benefit population through TIME and provided a selectable strategy of trastuzumab plus immunotherapy for HER2-positive breast cancer.
作者
杨闻箫
国琳玮
凌泓
胡欣
YANG Wenxiao;GUO Linwei;LING Hong;HU Xin(Department of Breast Surgery,Fudan University Shanghai Cancer Center,Department of Oncology,Shanghai Medical College,Fudan University,Shanghai 200032,China;Precision Cancer Medicine Center,Fudan University Shanghai Cancer Center,Department of Oncology,Shanghai Medical College,Fudan University,Shanghai 200032,China;Department of Colorectal Surgery,Fudan University Shanghai Cancer Center,Department of Oncology,Shanghai Medical College,Fudan University,Shanghai 200032,China)
出处
《中国癌症杂志》
CAS
CSCD
北大核心
2023年第5期484-498,共15页
China Oncology
关键词
肿瘤免疫微环境
曲妥珠单抗
免疫治疗
人表皮生长因子受体2阳性乳腺癌
预测模型
Tumor immune microenvironment
Trastuzumab
Immunotherapy
Human epidermal growth factor receptor 2-positive breast cancer
Prediction model